QPPV.COM KNOWLEDGE ASSESSMENT

Montelukast: Discovery, Development, Safety and Pharmacovigilance — Knowledge Assessment

Test your understanding of the concepts covered by Montelukast: Discovery, Development, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the regulatory meaning of the FDA's 2020 boxed warning?
Question 2 of 10 A reviewer is asked whether montelukast suppresses leukotriene production in the same way as a 5-lipoxygenase inhibitor. Which interpretation is most accurate?
Question 3 of 10 An adult develops worsening depression and suicidal thoughts after stopping montelukast, which had been stopped because of insomnia. What is the most appropriate case interpretation?
Question 4 of 10 Why did the FDA advise reserving montelukast for allergic rhinitis when alternative therapies are inadequate or not tolerated?
Question 5 of 10 How should the UK MHRA's 2024 action be distinguished from the FDA's 2020 action?
Question 6 of 10 A pregnancy case is assessed using US and UK product information that phrase pregnancy recommendations differently. Which conclusion is most appropriate?
Question 7 of 10 Which activity best evaluates whether montelukast risk-minimisation communication is effective?
Question 8 of 10 A patient develops new suicidal thoughts while taking montelukast. Which response best reflects the article's clinical and pharmacovigilance priorities?
Question 9 of 10 A caregiver reports nightmares, irritability and school difficulties in a child soon after montelukast was started, with improvement after it was stopped. Which follow-up is most useful?
Question 10 of 10 A reviewer sees that a UK SmPC classifies a particular neuropsychiatric reaction as very rare, while the assessed US label lists it without a frequency estimate. What is the best practice?

Select an answer to continue.

QPPV.com